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Eukaryotes and prokaryotes possess fatty acid synthase (FAS) biosynthetic pathways that comprise iterative
chain elongation, reduction, and dehydration reactions. The bacterial FASII pathway differs significantly from
humanFASpathwaysand is a long-standing target for antibiotic development againstGram-negative bacteria due
to differences from the human FAS, and several existing antibacterial agents are known to inhibit FASII enzymes.
N-Acetylcysteamine (NAC) fatty acid thioesters have been used as mimics of the natural acyl carrier protein
pathway intermediates to assay FASII enzymes, and we now report an assay of FabV from Pseudomonas
aeruginosa using (E)-2-decenoyl-NAC. In addition, we have converted an existing UV absorbance assay for
FabA, the bifunctional dehydration/epimerization enzyme and key target in the FASII pathway, into a
high-throughput enzyme coupled fluorescence assay that has been employed to screen a library of diverse
smallmolecules.With this approach,N-(4-chlorobenzyl)-3-(2-furyl)-1H-1,2,4-triazol-5-amine (N42FTA)was found
to competitively inhibit (pIC50 = 5.7 ± 0.2) the processing of 3-hydroxydecanoyl-NAC by P. aeruginosa FabA.
N42FTAwas shown to be potent in blocking crosslinking ofEscherichia coli acyl carrier protein and FabA, a direct
mimic of the biological process. The co-complex structure of N42FTAwithP. aeruginosaFabA protein rationalises
affinity and suggests future design opportunities. Employing NAC fatty acid mimics to develop further
high-throughput assays for individual enzymes in the FASII pathway should aid in the discovery of new
antimicrobials.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
The routine availability of antibiotics that could
rapidly cure bacterial infections that had once been
fatal was one the most important developments of
20th century medicine. Still, the World Health
Organisation pointed out in its 2014 Antimicrobial
Resistance report that bacteria have developed
resistance to even highly effective antibiotics within
a few years of their introduction. The United King-
dom's Chief Medical Officer's annual report in 2011Authors. Published by Elsevier Ltd. T
rg/licenses/by/4.0/).highlighted that antibiotic resistance was likely to
become widespread and present a very serious
threat to human health without intervention.
Fatty acids are essential in all cells, but the
differences between the type II system (FASII) in
bacteria and the type I system (FASI) of eukaryotes
such as humans (mitochondria have a FASII
pathway that it is significantly different [1]) have
made FASII an attractive target for antimicrobial
research [2,3]. The validity of the pathway as a drug
target in Gram-positive bacteria has been
his is an open access article under the CC BY license
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109High-Throughput Assay of the FabA Proteinquestioned by experiments showing that exogenous
fatty acids found in human hosts can rescue bacteria
where FASII genes have been knocked out [4].
However, the relevance of these gene knockout
studies to actual infection models is disputed [5], and
the validity of FASII as a clinically useful target for
Gram-positives remains unclear. The rationale of
targeting FASII in Gram-negative bacteria, however,
remains unchallenged as these organisms require
β-hydroxy-fatty acids that cannot be sourced from
the human host [6].OH O
O
C5H11
C5H11
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Fig. 1. Type II fatty acid synthesis pathway. (a) FabD cataly
to an ACP. The malonyl-ACP is then condensed with acyl-CoA
substrate of the elongation cycle, acetoacetyl-ACP (a 1,3-dik
β-ketoacyl-ACP to a β-hydroxyacyl-ACP by FabG. The β-hydro
FabA). FabA (only) isomerises (E)-2-enoyl-ACP to (Z)-3-eno
reduced by FabI, and successive rounds of extension and re
catalysed by FabB (synthase I) (or the closely related sy
xydecanoyl-NAC act as mimics of the ACP-linked substrates.In FASII, distinct enzymes catalyse the different
chemical steps of the cycle (Fig. 1a) and several
enzymes in FASII have been investigated as
potential drug targets [7]. The potency of the FabI
inhibitors triclosan and isoniazid [8] has spurred a
large programme of research to develop new FabI
inhibitors [9]. Nevertheless, isozymes of FabI have
been identified (FabV in Pseudomonas aeruginosa
and Vibrio cholerae, FabL in Bacillus subtilis, and
FabK in Streptococcus pneumoniae, Enterococcus
faecalis, and Enterococcus faecium) underminingS
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ses the transfer of the malonyl group from the malonyl-CoA
, catalysed by FabH (ketoacyl synthase III), to form the firs
etone). The next step of the cycle is the reduction of the
xyacyl-ACP is dehydrated to (E)-2-enoyl-ACP by FabZ (o
yl-ACP. The trans C2–C3 carbon–carbon double bond is
duction follow. Subsequent malonyl-CoA condensation is
nthase II, FabF). (b) (E)-2-Decenoyl-NAC and 3-hydrot
r
-
110 High-Throughput Assay of the FabA Proteinthe broad spectrum of FabI-selective inhibitors [10].
As a specific example, FabV (enoyl-ACP reductase)
confers resistance to triclosan in P. aeruginosa [11–
13]. Drug development programmes are underway
against the synthases FabB, FabH, and FabF
spurred by the discovery of platensimycin [14], a
potent inhibitor of FabB/FabF. The FASII cycle has
been assayed as a complete unit in a high-through-
put manner allowing novel inhibitors to be identified
for β-ketoacyl-acyl carrier protein (ACP) synthases
(FabF and FabB) [15] but this approach did not
disclose inhibitors of other FASII target enzymes
notably FabA (3-hydroxyacyl-[ACP] dehydratase),
FabZ, or FabG (3-oxoacyl-[ACP] reductase). The
inability to identify inhibitors could have arisen from
multiple causes including a lack of druggability of
these enzymes, which would make them poor
targets for further study.
Fragment-based discovery [16–19] has identified a
number of compounds that bind to FabZ and are
predicted to block (and thus inhibit) the binding of
substrate (ACP-linked fatty acids). FabA, a homologue
of FabZ, is an essential enzyme for Gram-negative
bacteria [20,21]. Unlike FabZ, FabA carries out a
second enzymatic step, the isomerisation of
(E)-2-enoyl-ACP to (Z)-3-enoyl-ACP (trans to cis C3–
C4 double bond), an essential reaction to provide
unsaturated fatty acids [22,23] that are furthermore
absent in eukaryotes (Fig. 1a). Subtle differences in the
structure of the substrate binding pockets [23–25]
mean that, whilst FabA is an effective replacement for
FabZ, FabZ cannot replace FabA. Further, unlike FabI,
there are no isozymes of FabA. This makes FabA a
particularly attractive target for drug discovery [26]. A
suicide inhibitor that has an alkyne group in a specific
position of fatty acid analogue [3-decynoyl-N-acetyl-
cysteamine (NAC)] [22,27] has been described for
FabA but its use is as a research tool. We have
previously described compounds that bind to FabA
using fragment screening [24] but no high-throughput
assay of FabA (or FabZ) has been reported.
We previously reported a high-throughput NADPH
fluorescent assay for FabG using a substrate mimic
3-hydroxydecanoyl-NAC (Fig. 1b) and identified
several novel inhibitors; establishing the protein is
druggable. Since hits against (druggable) FabG
were not discovered by the whole pathway assay,
this assaymay be not well suited to identify weaker, but
none the less promising, inhibitors of all potential target
enzymes in the FASII pathway. Here, we report an
assay for PaFabV using (E)-2-decenoyl-NAC as
substrate mimic (Fig. 1b) and for PaFabA by
coupling PaFabA with PaFabV using 3-hydroxyde-
canoyl-NAC as a substrate mimic (Fig. 1b). The
coupled assay is compatible with the needs
of high-throughput screening based on the fluores-
cent measurement of NADH consumption that
has been devised. Using this assay and a library
of 15,667 small, lead-like compounds, we describethe identification and characterisation of the first
non-covalent in vitro inhibitor of FabA. The crystal
structure reveals that the compound binds at
the active site and anchors to the key catalytic
residues.Results and Discussion
N-acetylcysteine (NAC) fatty acids as ACP fatty
acid mimics
The natural ACP protein substrates of the FASII
pathway are too challenging to be employed as
assay reagents for high-throughput screening, and
this has driven the use of substrate mimics such as
CoA thioesters for assay development. One of the
first reports of FabA activity showed that 3-hydro-
xydecanoyl-NAC was a substrate, albeit poorer than
the natural ACP-linked substrate [28]. We have
previously shown that 3-hydroxydecanoyl-NAC is a
substrate that can be used to assay FabG [29] by
running the FabG in the reverse direction (Fig. 1a).
We have now shown that (E)-2-decenoyl-NAC is a
substrate of PaFabV allowing consumption of NADH
to be monitored (Fig. 2a). The low solubility of the
substrate analogue prevented enzyme saturation,
precluding detailed kinetic characterisation, but will
allow, in principal, high-throughput screening for
inhibitors. (E)-2-Decenoyl-NAC was also shown to
be a substrate for PaFabI (a PaFabV isozyme) (Fig.
S1) and we predict that the third isozyme FabL could
be assayed in the same manner. The execution of all
three isozymes in parallel high-throughput assays
would disclose which inhibitors (such as triclosan)
are effective only against specific isozymes. In
contrast to the whole pathway assay, the individual
enzyme approach.
Using the 3-hydroxydecanoyl-NAC substrate mimic
andmonitoring absorbance at 260 nm,wewere able to
reproduce a previously described assay [30,31] for the
first dehydration step catalysed by FabA (Fig. 2b).
Substrate solubility once again limited our ability to
carry out a full kinetic characterisation. We would ex-
pect FabZ to be assayable in the same way as FabA.
However, we have been unable to express soluble
FabZ from either Escherichia coli or P. aeruginosa.
Expression of soluble PaFabZ has been reported [23],
andweattribute our failure to reproduce thiswork to our
use of slightly different constructs (original clone was
not available).
FabA high-throughput assay
The direct UVabsorbance assay for FabA (Fig. 2b) is
not suitable for high-throughput screening, as many
library compounds contain aromatic heterocycles,
which have appreciable absorbance at 260 nm. We
Fig. 2. The use of NAC fatty acid mimics to assay
individual proteins in the FASII cycle. (a) Incubation of
(E)-2-decenoyl-NAC and PaFabV in the presence of
NADH leads to formation of decanoyl-NAC. The consump-
tion of NADH can be monitored by fluorescence. (b)
Incubation of 3-hydroxydecanoyl-NAC with PaFabA that
converts it into (E)-2-decenoyl-NAC. The formation of the
double bond can bemonitored by direct UVmeasurement. (c)
The log-dose response ofN42FTA in the direct (UV) assay for
PaFabA, each point is an average of three measurements
and the error bars represent the standard deviation.
111High-Throughput Assay of the FabA Proteinexplored two alternative approaches, firstly reversing
the normal direction of catalytic activity by incubating
(E)-2-decenoyl-NAC with PaFabA and PaFabG
(in excess) and monitoring the production of NADPH.Secondly, incubating 3-hydroxydecanoyl-NAC with
PaFabA and PaFabV (in excess) and monitoring
consumption of NADH. Both these coupled assays,
like the direct assay, rely on the first dehydration
reaction. Despite observing turnover (Fig. S2)
and adding a significant excess of PaFabG, we
were unable to demonstrate that PaFabA was rate
limiting. However, the coupled PaFabA and PaFabV
system proved a robust measure of PaFabA activity
(Fig. 3a–c). Determination of accurate kinetic
parameters was hindered by the insolubility of 3-hydro-
xydecanoyl-NAC, and we estimated the KM value as
400 μM for this substrate with PaFabA (Fig. 3d). A
high-throughput assay against 15,667 compounds
was carried out (Fig. 4a and b) with a mean Z′ factor
of 0.4 ± 0.1 (statistical measure of assay response;
ideal values are N0.5) and themean percent coefficient
of variation was 5.6 ± 1.3 (ideal values are b10)
indicating that the assay is reliable [32,33]. After
elimination of fluorescent compounds (Fig. 4c), the 13
remaining “hit” compounds were tested to identify
those with concentration-dependent inhibition.
N-(4-Chlorobenzyl)-3-(2-furyl)-1H-1,2,4-triazol-5-a-
mine (N42FTA) alone exhibited this behaviour, with an
IC50 of 2 μM (pIC50 of 5.7 ± 0.2) (n = 6; Fig. 4d). With
the use of the direct UV assay, non-linear regression
gavean IC50 valueof 3.27 μM(pIC50of 5.5) forPaFabA
(Fig. 2c) and of 2.31 μM (pIC50 of 5.6) for EcFabA (Fig.
S3). The binding constant of N42FTA to PaFabA,
measured by isothermal titration calorimetry, was 4 μM
(Fig. 4e).
Biological activity of N42FTA
A key question is whether the inhibitor is potent
against the natural ACP-linked substrate, rather than
just against NAC analogues. Mechanistic cross-
linking of ACP-dependent enzymes with their cog-
nate ACPs has been demonstrated to be a powerful
tool to understand the protein–protein interactions
that regulate these catalytic events [34,35]. This is
achieved by tethering an active-site warhead to the
ACP via a modified pantetheine arm so that the
warhead covalently attaches to an active-site resi-
due of the cognate protein when the ACP is bound to
its cognate protein. The sulfonyl-3-alkyne-modified
ACP was shown to specifically crosslink to FabA [36]
leading to a stable ACP = EcFabA complex that can
be visualised by SDS-PAGE [37,38] and resulted in
structural characterisation of the complex. Pre-incu-
bating EcFabA with 250 μM N42FTA reduces cross-
linking by 94% when compared to a control with no
inhibitor (Fig. 5). Thus, the compound does indeed
function as an inhibitor of the biologically relevant
process. Direct addition of N42FTA to a Caenorhab-
ditis elegans model of P. aeruginosa infection [39]
and to E. coliCWG296 (F470waaP∷aacC1) did not,
however, reveal antibacterial activity, which we
attribute to lack of penetration.
Fig. 3. PaFabA–PaFabV coupled assay development. (a) A linear response in detected activity is observed when the
amount of PaFabA was varied in the presence of an excess of PaFabV (1.6 μM). Each point is a replicate of three
independent measurements, and error bars are standard deviations. (b) A plateau in detected activity is observed when
the amount of PaFabV was varied in the presence of 400 nM PaFabA. Each point is an average of two independent
replicates, and consequently, no error bars are plotted. (c) Increasing the concentration of NADH when added to PaFabV
incubated with (E)-2-decenoyl-NAC leads to a plateau. Each point is an independent replicate of three measurements, and
error bars are standard deviations. (d) A Michaelis–Menten plot for 3-hydroxydecanoyl-NAC in the coupled PaFabA–
PaFabV assay with kinetic constants. Lack of solubility limits the concentration of 3-hydroxydecanoyl-NAC and our ability
to saturate the enzyme. Each point is an independent replicate of three measurements, and error bars are standard
deviations. (e) A time course shows that the final conditions for the high-throughput assay give a linear response over
60 min (black circle). No turnover is detected in absence of PaFabA (open circle). Each point is an average of eight
independent measurements.
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Fig. 4. Identification of an inhibitor. (a) Distribution of activity of 15,667 diverse small molecules in the FabA assay. A
total of 168 compounds gave more than 150% inhibition (range, 151–1767) and are represented by the bar after the x-axis
break. Negative inhibition values represent an increase in signal at 455 nm relative to control. (b) Correlation of the effect of
1056 selected active compounds tested in replicate, at a single concentration (10 μM). The 1056 molecules were chosen
as having N40% and ≤100% inhibition in the primary assay (a). (c) Black circles are plots of activity at PaFabA against
PaFabG for individual hit compounds. Inherently fluorescent compounds will give a negative value in the FabG but a
positive value in the FabA assay. A red broken line is a linear regression of these data. Compounds highlighted in red (and
expanded in the inset) were selected as potential FabA actives as they lay off the line of regression, had limited fluorescent
activity in the FabG assay (b50% increase in signal), and fell within a physically reasonable inhibition range against FabA
(N50%, b200%). (d) N42FTA (shown in the inset) was the only compound in this selection that inhibits FabA in a
concentration-dependent manner; pIC50 = 5.7 ± 0.2, Hill slope (nH) = 0.9. Each point was measured in six independent
experiments and error bars represent the standard deviations. (E) Isothermal calorimetry titration of N42FTA with PaFabA.
Top panel, raw titration data; bottom panel, the fitted isotherm using Origin software.
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To understand the mechanism of inhibition by
N42FTA, we determined its co-crystal structure with
PaFabA (Fig. 6a). N42FTA is bound at the active site
formed by the two subunits of the canonical FabA
dimer, and it bridges from the A subunit to the Bsubunit. Therefore, each dimer has two compounds
bound (Fig. 6b). One nitrogen atom of the central
triazole ring makes a hydrogen bond with main chain
of A195 in the A subunit whilst the other two nitrogen
atoms make hydrogen bonds to H70 and G79 in the
B subunit. One water (W1), found in all five
monomers in the asymmetric unit, bridges from the
Fig. 5. Evaluation of N42FTA inhibition of ACP = FabA
complex formation. Probe 1 was appended to apo-ACP
using a one-pot chemoenzymatic method for 3 h to form
crypto-ACP [37]. EcFabA along with N42FTA ranging from
0 to 250 μM was added to the one-pot reaction and
reacted for an additional 24 h. The inhibition of ACP and
EcFabA crosslinking was monitored by 12% SDS-PAGE
using Coomassie stain and analysed by ImageJ [45].
114 High-Throughput Assay of the FabA Proteintriazole to the side chain of D84 of the A subunit and
the main chain of C80 of the B subunit (Fig. 6c). A
second water (W2), which is absent in two mono-
mers of the asymmetric unit, bridges the triazole ring
and the amine of N42FTA to the key catalytic
residues H70 of the B subunit and D84 of the A
subunit (Fig. 6c). The triazole group can be
described as a pin joining the monomers through a
network of hydrogen bonds. The electron densities
for the oxygen and carbon atoms of the furan ring are
not distinguishable experimentally; thus, the orien-
tation of the furan ring depends upon judgement. In
the E subunit, the orientation seems clear, as the
ring oxygen makes a weak hydrogen bond (3.5 Å) to
the backbone amide of G79. However, in the other
subunits, the orientation is ambiguous as there is no
hydrogen bond. In the other orientation, there would
be a favourable polar contact (the geometry is not
consistent with a hydrogen bond) to the backbone
nitrogen of A105 and an unfavourable polar interac-
tion with the backbone oxygen atom (lone pair to
lone pair). We conclude that both orientations are
possible. The chlorobenzene moiety makes very
extensive van der Waal contacts filling the hydro-
phobic tunnel in the A subunit that binds the
substrate acyl chain (Fig. 6c and d). These data
suggest that N42FTA acts by blocking acyl chain
substrate binding.
Superposition of the N42FTA complex with the
structure of H70N (inactive) PaFabA bound to
3-hydroxydecanoyl-NAC reveals that the triazole
occupies the same volume as the thioester group
of 3-hydroxydecanoyl-NAC (Fig. 6d). W1 in the
N42FTA complex occupies the same position as
the mechanistically important water (also labelled
W1) in H70N PaFabA 3-hydroxydecanoyl-NAC
(Fig. 6d). A second water is also present in bothstructures but it is shifted by over 1 Å in the N42FTA
complex compared to the substrate mimic; in the
N42FTA complex, it occupies, in part, the volume
occupied by C4 of the substrate mimic (Fig. 6d).
Interestingly, superimposing the N42FTA complex
onto the PaFabZ structure [23] reveals that the
chlorobenzene moiety would clash with both L11
and L86 of PaFabZ, suggesting that the compound
may be specific for FabA (Fig. 7a). This difference is
a reflection of the wider hydrophobic tunnel in
PaFabA (than in PaFabZ) that allows for the cis–
trans isomerization that is uniquely catalysed by
FabA. Several small molecules that bind weakly
(0.5–10 mM) to PaFabA have been identified previ-
ously by so-called fragment discovery methods [24].
Superposition of the N42FTA complex structure with
the complexes of the fragments (Fig. 7b) shows that
the furan ring N42FTA occupies similar volume to
five-membered rings present in the fragments,
suggesting to us that this is a key motif in future
design. In N42FTA, since the furan ring does not
make ideal hydrogen bonds, other heterocyclic rings
could be usefully explored to pick up further
interactions. In the fragment complexes, linear
atoms' chains occupy a similar region of protein
structure (the catalytic site) to that of triazole ring of
N42FTA, and the success in filling this volume may
in part explain the higher affinity of N42FTA.
Interestingly, N42FTA does not make more hydro-
gen bonds (Fig. 6c) than some of the much weaker
binding fragments. There are two notable differ-
ences between N42FTA and the fragments. Firstly,
that the chlorobenzene moiety of N42FTA extends
much more deeply into the enzyme's hydrophobic
tunnel that binds the substrate and further filling of
this tunnel may increase significantly the binding
affinity. Secondly, N42FTA does not make any
interactions with the residues that form the pan-
tetheine binding region that is used by fragments,
allowing room for compound elaboration.Conclusions
3-Hydroxydecanoyl-NAC and (E)-2-decenoyl-NAC
are stable compounds that are mimics of ACP-linked
fatty acids, critical intermediates in the bacterial FASII
pathway. The mimics are much easier to make in
quantity than the natural ACP substrates or coenzy-
me-A-linked fatty acids reported in assays of the FASII
pathway [15,19,31]. Although a robust high-through-
put assay exists for the entire FASII pathway in vitro,
no inhibitors of either FabGor FabA, two enzymes that
catalyse very different but essential reactions, were
reported by this approach [15]. High-throughput
screening of the PaFabA enzyme has discovered a
new inhibitor, N42FTA, the first non-suicide inhibitor of
this important and attractive target. We further
demonstrate that N42FTA inhibits the functional
Fig. 6. Crystal structure of PaFabA complex with N42FTA. (a) Fo − Fc electron density omit map at 3σ around the
N42FTA. The compound is shown as sticks with carbon atoms coloured yellow, chlorine coloured green, nitrogen coloured
blue, and oxygen coloured red. The A subunit of the protein is coloured cyan and the B subunit is coloured pale blue. (b)
Two molecules of N42FTA bind to the PaFabA dimer, and each N42FTAmolecule binds at the protein dimer interface. The
colour scheme is as (a). (c) Stereo view of N42FTA binding site. Residues within 4.0 Å of the compound are displayed and
hydrogen bonds are shown as black broken lines. The colour scheme is as (a), with the carbons from the A subunit
coloured cyan and those from the B subunit coloured pale blue. The conserved water, W1, labelled and the additional
water (found in all but two subunits) is marked W2. A ligplot diagramme for the interaction is given in Fig. S4. The two
catalytic residues (H70 and D84) have been highlighted in green. (d) Superposition of the N42FTA PaFabA complex with
the previously reported 3-hydroxydecanoyl-NAC PaFabA complex [24] reveals that the compound matches the volume of
the substrate mimic very well. The colour scheme is as (a) for the N42FTA PaFabA complex but the carbons of
3-hydroxydecanoyl-NAC are coloured grey, the S atom is in orange, and the two water molecules are in pink.
115High-Throughput Assay of the FabA Proteincrosslinking assay of AcpPwith FabA, indicating that it
blocks the native ACP substrate–enzyme complex
formation. A crystal structure of the FabA co-complex
with N42FTA reveals that the compound binds at the
active site, making interactions with key catalyticresidues and preventing binding of the natural
ACP-linked substrate, providing a platform for future
elaboration of the N42FTA scaffold. We believe that
individual enzyme screening of FASII enzymes
demonstrated here offers a significant resource in
(a) (b)
Fig. 7. Specificity ofN42FTAandopportunities for further design. (a)Superposition ofN42FTAPaFabAcomplex andPaFabZ
[23]. The colour scheme of the atoms from the PaFabA complex is as Fig. 6a, atoms from the A subunit of PaFabZ are coloured
dark green and the B subunit is in blue. The side chains of L11 and L86 fromPaFabZ clash with the chlorobenzene group due to
changes in the hydrophobic tunnel that are key to the differences in FabA and FabZ activity. Space-fill representations of the
tunnels are shown in Fig. S5. (b) Superposition of N42FTA complex and the four fragment complexes previously reported [24].
116 High-Throughput Assay of the FabA Proteinthe search for novel antibiotics. The use of larger
libraries with this assay can be expected to provide
further compounds for inhibitor development along
with structure-guided optimisation.
Materials and Methods
Materials
NAC, 4-dimethylaminopyridine, and 3-ethyl-1-(3-di-
methylaminopropyl)carbodiimide hydrochloride were pur-
chased from Sigma-Aldrich; trans-2-decenoic acid was
from TCI. (±)-3-Hydroxydecanoic acid was from Wako
chemicals.
Synthesis NAC thioesters
The mimics were synthesised using a published
procedure by coupling the corresponding carboxylic acid
with NAC [40,41]. Briefly, a mixture of the carboxylic acid
(4.0 mmol), NAC (2.0 mmol), 4-dimethylaminopyridine
(2.0 mmol), and EDCI-HCl (4.6 mmol) in dichloromethane
(10 ml) was stirred at room temperature for 24 h. The
reaction mixture was washed with aqueous HCl (0.1 M,
10 ml) and the aqueous layer was extracted with
dichloromethane (5 × 10 ml). The organic layers were
combined, dried with anhydrous sodium sulfate, and the
solvent evaporated in vacuo. Silica gel chromatography
(80:20 ethyl acetate/light petrol) of the residue gave the
title compound identified by NMR, IR, and electrospray
ionisation mass spectrometry.
Expression and purification of fatty acid biosynthesis
enzymesPaFabA and PaFabG were produced as previously
described in Refs. [24] and [29]. The coding sequence for
PaFabV (locus tag†: PA2950) was amplified by PCRdirectly from the P. aeruginosa PA01 genome and was
cloned using a ligation-independent cloning method into
pNIC28-BSA4 [42] to create a cleavable (with TEV
protease) His6 TAG to aid purification [43]. The construct
was expressed in E. coli BL21 (DE3) in 1 l LB media
containing 30 μg/ml kanamycin inoculated with 1 ml
pre-culture. Cells were grown to an OD600 of 0.6, then
expression was induced (0.1 mM IPTG), and cells were
grown for a further 24 h at 20 °C. Cells were harvested by
centrifugation at 3300g and stored as pellets at −20 °C.
For purification, pellets were defrosted and resuspended in
lysis buffer [25 mM Tris–HCl (pH 8), 150 mM NaCl, and
10 mM imidazole], supplemented with DNase I (to 10 U/
ml, Roche) and lysozyme (to 4000 U/ml, Sigma), and
incubated at 37 °C for 1 h. Lysis was performed using
ultrasonication on ice (8 cycles of 30 s), and samples were
centrifuged at 40,000g for 20 min. The lysate was filtered
(45-μm filter) and applied directly to Ni-NTA resin (Qiagen).
The protein was eluted with buffer containing 100 mM
imidazole. The eluate was buffer exchanged into 25 mM
Tris–HCl (pH 8) and 150 mM NaCl using a PD-10 column
(GE Healthcare) and was digested overnight at 20 °C with
TEV protease (1:200 protease-to-PaFabV ratio, 2 mM
DTT) to remove the N-terminal His6 tag. An additional
Ni-NTA resin step facilitated removal of uncut PaFabV,
His6-tagged TEV protease, and other proteins bound
non-specifically. Cleaved PaFabV in the flow-through
was concentrated using Vivaspin columns (Sartorius)
and loaded to a S200 prep-grade gel-filtration column
(GE Healthcare) equilibrated with 25 mM Tris–HCl (pH 8)
and 150 mM NaCl and was eluted as a single peak. Pure
fractions were pooled and concentrated to 20 mg/ml, flash
frozen in aliquots of 200 μl in liquid nitrogen, and stored at
−80 °C.
FabV (UV and fluorescence) direct assay
The fluorescence assay was carried out in a 150-μl
fluorescence cuvette prepared with a pre-reaction mixture
containing 50 mM Tris (pH 7.5), 0.1% (w/v) BSA, 0.01%
Triton X100, 1 mM DTT (assay buffer), 250 μM NADH,
117High-Throughput Assay of the FabA Proteinand 9 nM of the enzyme. The reaction was started by
addition of 0.2 mM (E)-2-decenoyl-NAC and the decrease
of the NADH monitored using an excitation wavelength of
340 nm and an emission wavelength of 455 nm. The UV
assay was carried out with the same reaction mixture in a
500-μl UV cuvette. The decrease of the NADH was
monitored at 340 nm after addition of 0.2 mM (E)-2-
decenoyl-NAC (Fig. 2a).
FabA (direct UV assay)
The assay relies on the absorbance of (E)-2-dece-
noyl-NAC at 260 nm. The substrate of the reaction,
3-hydroxydecanoyl-NAC, shows little absorbance as it
lacks the conjugated double bond. The reaction was
carried out in a 500-μl UV cuvette prepared with a
pre-reaction mixture in the same assay buffer as above
with 750 nM of the enzyme (Fig. 2b). The reaction was
started by addition of 0.4 mM 3-hydroxydecanoyl-NAC
and the increase of the absorbance monitored at 20 °C.
The same assay has been used to verify the high--
throughput assay hit, and the inhibitor was first dissolved
in dimethyl sulfoxide and added to the same pre-reaction
mixture in the cuvette. Final concentrations of the
inhibitor were varied from 100 to 0.25 μM. The IC50 was
estimated by fitting the data to a dose–response curve
using GraphPad Prism software.
FabA–FabV coupled assay
To develop a robust high-throughput assay, we had to
determine optimal concentrations of PaFabA, PaFabV,
and NADH. 3-Hydroxydecanoyl-NAC (300 μM) was
incubated with varying concentrations of PaFabA (50–
750 nM), in the presence of an excess of PaFabV
(1.6 μM) and NADH (250 μM) in the same buffer as
used in the PaFabV assay. The reaction was performed
at room temperature for a period of 60 min and the
resulting decrease in fluorescence intensity was moni-
tored. Figure 3a demonstrates a clear linear relationship
between PaFabA enzyme concentration and initial
reaction rate; a concentration of 400 nM was determined
to produce a robust signal suitable for screening. Varying
concentrations of PaFabV (4 nM–1.6 μM) were incubat-
ed with PaFabA (400 nM) and NADH (250 μM) (Fig. 3b).
To ensure that PaFabA was the rate-limiting step, we set
the concentration of PaFabV to 1.6 μM for subsequent
screening. High concentrations of NADH are not desir-
able for a high-throughput fluorescence assay as inner
filtering effects can lead to problems in interpretation. The
optimal NADH concentration (signal to noise, time of
reaction) of 250 μM was identified by assaying PaFabV
(alone) with 200 μM (E)-2-decenoyl NAC (Fig. 3c). Deter-
mination of an optimal substrate concentration was
compromised by the limited solubility of 3-hydroxydeca-
noyl-NAC. Initial rates were plotted from 10 replicates
by plotting the linear portion of the reaction. A three-para-
meter non-linear regression fit was performed using XLFit
(IDBS), using standard equation 250: V = Vmax ×
[substrate]n/(KM
n + [substrate]n) (Fig. 3d). A time course
of the final coupled assay conditions (3-hydroxydeca-
noyl-NAC, 400 μM; PaFabA, 400 nM; PaFabV, 1.6 μM;
NADH, 250 μM) shows a linear response over 60 min(Fig. 3e). Omission of FabA resulted in no detectable
substrate turnover (Fig. 3e).
High-throughput screening
Initially, 25 μl of assay buffer supplemented with
3.2 μM PaFabV and either with or without PaFabA
(800 nM) was added to 384-well, black polystyrene,
high-binding microtitre plates (Greiner Bio-One) using a
WellMate (Matrix). The reaction was started by the
addition of assay buffer supplemented with 0.6 mM
3-hydroxydecanoyl-NAC in a volume of 25 μl also using
the WellMate, such that the final concentrations of
enzymes and substrate were 250 μM NADH, 1.6 μM
PaFabV, 400 nM PaFabA, and 0.3 mM hydroxydeca-
noyl-NAC. Plates were incubated for 40 min at room
temperature with constant agitation. The conversion of
NADH into NAD+ was measured as a decrease in
fluorescence using the EnVision microplate reader
(Perkin Elmer). On-the-fly readings were performed
using an excitation wavelength of 340 nm and an
emission wavelength of 455 nm. Compounds from a
library of 15,667 compounds (Dundee Drug Discovery
Unit in-house diverse compound collection) [44] were
screened at a single concentration (10 μM) following the
procedure described for the FabA–FabV coupled assay.
The recorded fluorescence data were processed
using ActivityBase software (IDBS) and further analysed
using Vortex (Dotmatics Limited). The distribution of
activity is illustrated in Fig. 4a. Compounds with an
activity greater than 3× standard deviation over the
baseline were considered as active in this assay.
However, for pragmatic reasons, a limited subset of
1056 compounds exhibiting percentage inhibitions of
N40% and ≤100% were chosen for further analysis at a
single concentration (10 μM, n = 2); a good correlation
between percentage inhibition was observed between the
two replicates (Fig. 4b). A total of 171 compounds with an
average percentage inhibition of N60% were taken into
10-point concentration effect curves. A total of 20
compounds failed to reach 50% inhibition. Further 85%
of the remaining compounds showed significant activity in
a fluorescence exclusion assay in the absence of enzyme
(all other components present). The observation of such
a high-false-positive identification led us to refine our hit
selection algorithm.
Data from the FabA screen were re-analysed and
compared with data obtained from a compound screen
against FabG [29]. The correlation between the data from the
two screens is illustrated in Fig. 4c. Due to the different nature
of the chemical assay (inhibition of FabA yields a reduction in
fluorescence at 455 nmwhilst inhibition of FabG results in an
increase), compounds that lie close to the line of correlation
were reasoned to be the result of changes in the molecules'
inherent fluorescence rather than inhibition. A selection of
molecules that (a) inhibited FabA in the range from N50 to
b200 and that (b) did not increase the signal in the FabG
assay by N50% were selected. This resulted in 13
compounds being selected (highlighted in red symbols in
the main part of Fig. 4c and expanded in the inset). Only one
N42FTAshowed concentration-dependent inhibition of FabA
(Fig. 4d). This compound had previously been identified as of
interest using the initial hit identification algorithm but had not
been progressed further due to the high number of higher
potency hits (subsequently identified as false positives).
Table 1. Crystallographic data and refinement statistics
PaFabA-N42FTA
Data collection
Space group C2
Cell dimensions
a, b, c (Å) 115.6, 142.9, 77.9
α, β, γ (°) 90, 116.5, 90
Resolution (Å)a 50.00–2.41 (2.47–2.41)
Rmerge 0.067 (0.625)
I/σ(I) 17.5 (2.3)
Completeness (%) 97.4 (94.8)
Average redundancy 3.9 (3.6)
Z′ 5
Refinement
Resolution (Å) 2.41
No. of reflections 42,735
Rwork/Rfree 18.4/21.2
No. of atoms
Protein 6551
Water molecules 271
Compound 95
B-factors (Å2)b
Protein 43
Chain B-factor range 38 (E) to 51 (C)
Water 35
Inhibitor 36
Inhibitor B-factor range 30 (B) to 41 (C)
r.m.s. deviations
Bond lengths (Å) 0.012
Bond angles (°) 1.27
Ramachandran plots summery (%)c 97.1/2.9/0
a
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The affinity of N42FTA for PaFabA was measured by
isothermal titration calorimetry using a VP-ITC instrument
(GE Healthcare) at 20 °C. Titrations were performed using
57-μl injections of 400 μM of the ligand in 30 μM PaFabA
in the same buffer [100 mM sodium phosphate (pH 7.5)
and 7.5% DMSO]. The heats of dilution measured from
injection of the ligands into the buffer were subtracted from
the experimental data and titration curves were fitted to a
single-site binding using Origin software (Fig. 4e).
ACP and FabA crosslinking
Sulfonyl-3-alkynyl-ACP was prepared from a reaction
mixture containing 50 mM potassium phosphate (pH 7.4),
8 mM ATP, 12.5 mM MgCl2, 0.01 μg/μl MBP-CoaA,
0.01 μg/μl MBP-CoaD, 0.01 μg/μl MBP-CoaE, 0.004 μg/μl
Sfp, 0.3 μg/μl rhodamine-ACP, and 1 mM 3-sulfonyl-alkyne
pantetheine probe [37]. The mixture was gently mixed and
incubated at 37 °C for 12 h to form crypto-ACP. EcFabA
was added to the crypto-ACP reaction mixture at a final
concentration of 30 μM along with N42FTA at concentra-
tions ranging from 0 to 250 μM and reacted at 37 °C for an
additional 24 h. The reaction was stopped by the addition of
2× loading dye and monitored by 12% SDS-PAGE. The gel
was scanned by a Typhoon fluorescence imager at 580 nm
and rhodamine-ACP fluorescencewas quantified by ImageJ
[45] (Fig. 5).
Crystallisation and structure determination
Numbers in parentheses represent statistics in the high-
est-resolution shell.
b The lowest and highest B-factors were calculated by
averaging all protein and all inhibitor atoms in each chain in the
asymmetric unit. The chains giving rise to the lowest and highest
values are given in parentheses.
c Percentage (%) of residues in most favoured regions/allowed
regions/disfavoured.N42FTA (1 mM) was incubated for 1 h with PaFabA at
7 mg/ml before setting the plates. Crystals appeared at
20 °C after 2 days from a hanging drop of 2 μl of protein
solution with 1 μl of reservoir solution containing 0.1 M
lithium sulfate, 12% polyethylene glycol MME 5000, and
0.1 M sodium citrate (pH 5). Crystals were cryoprotected
by supplementing the mother liquor with 15% glycerol.
Data were collected in-house using a Rigaku Micro-
max™-007HF Cu anode with VariMax optics and a
Rigaku Saturn 944+ CCD detector. Data were proc-
essed with xia2 [46–50]. The structure was solved using
the coordinates of the wild-type PaFabA [42] and the
programme Phaser [51]. PHENIX [52] was used for
autobuilding from molecular replacement solution. The
model was adjusted with Coot [53] after each round of
refinement in REFMAC 5.6 from the CCP4 programme
suite 6.2.0 with local NCS restraints (option in pro-
gramme) and TLS parameters [54] applied throughout.
N42FTA was added to the model when the difference
electron density was clear (Fig. 6a). Coordinates and
topologies of ligand were generated by PRODRG [55].
The quality of the structure was checked with MolProbity
[56]. Final refinement statistics are given in Table 1.
Figures were drawn using PyMOL [57].
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